Buy37m
European Opportunities underperforms against benchmark, but optimistic
European Opportunities Trust invests in European companies offering capital growth and is managed by Devon Equity Management Ltd. The company said net asset value per share fell 8.6% to 921.66 pence ...
Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity
FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. Click here to find out why LFVN stock is a ...
Zacks.com on MSN19h
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...
3 Cheap Growth Stocks You Can Buy for Less Than $100
If you're looking for cheap growth stocks to buy, three you'll want to consider today are Novo Nordisk ( NVO 3.76%), Carnival ...